Dedicated view
After Conservative / Palliative Care
This view includes only public records whose official title or study scope explicitly states advanced, metastatic, recurrent, refractory, later-line, supportive care, or palliative. TrialBeacon makes no screening judgment, matching, or recommendation — it simply gathers the literally relevant official entries together and provides direct links to the originals. Whether a record is still open, or relevant to any individual situation, should be determined from the official original and your physician’s judgment.
Showing the verified snapshot of official records indexed on 2026-08-16. Every link opens the live original page.
Includes only public records whose official title explicitly mentions advanced / recurrent / later-line / supportive care. No recommendations, no matching — only links to the originals. Defer to the official page and your physician’s judgment.
Please read this first. A record appearing here does not mean it is open, available or appropriate for any individual. Inclusion is based only on wording in the official record — never on any judgement by this site. Discuss anything you find with your treating doctor.
Trial records retrieved live from the ClinicalTrials.gov public API.
Select the public official records you want to take to your appointment, then generate a list. Nothing is ranked or recommended — the list only reproduces titles and links.
Not signed in — up to 5 records per list. Sign in for higher free limits, or see Pro for more exports.
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
HTL0039732 in Participants With Advanced Solid Tumours
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
NCI COVID-19 in Cancer Patients, NCCAPS Study
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Roll-over Study to Allow Continued Access to Ribociclib
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
TLR9 Immunotherapy for Peritoneal Carcinomatosis
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)
NK521 in the Treatment of Advanced Solid Tumors
ChiCTR — Chinese Clinical Trial Registry, public search
CTIS public register — search clinical trials authorised in the EU/EEA
ESMO Clinical Practice Guidelines — supportive and palliative care section
FDA — expanded access (compassionate use) information for patients
NCCN Guidelines — palliative care category listing
NCCN Guidelines for Patients — plain-language versions
药物临床试验登记与信息公示平台 — national registry of drug trials conducted in China
Whether a record is still open, current, or appropriate for any individual can only be confirmed by the official source and your treating doctor.
Ways to open the conversation with your doctor (reference only, not advice)
A template only — it teaches how to ask, and gives no answers. Adapt these to your own situation.
- Are these public records still searchable or open to enrolment?
- From the literal wording of the public titles, is there any point relevant to the current situation?
- If there is something relevant, what should I ask you about next?
- For symptoms, pain or supportive care, is there a public guideline worth prioritising as a reference?
These are only examples to help you start a conversation. They are not medical advice. All decisions should be made together with your treating doctor.